ADCC-Enhanced Anti-Human PD-L1 (CS1001) Antibody, a biobetter (CAT#: BioBet-CB-026LX) Datasheet

Target
PD-L1
Isotype
IgG4
Description
ADCC-Enhanced Anti-Human PD-L1 (CS1001) Antibody is a glycosylation-modified anti- therapeutic antibody. Creative Biolabs' Afuco™ technology platform allows control of glycosylation level, thereby achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
Indication
Chronic lymphocytic leukemia; follicular lymphoma; some types of non-Hodgkin lymphoma (NHL);some non-cancer related illnesses
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
CD274 molecule
Full Name
CD274 molecule
Background
This gene encodes an immune inhibitory receptor ligand that is expressed by hematopoietic and non-hematopoietic cells, such as T cells and B cells and various types of tumor cells. The encoded protein is a type I transmembrane protein that has immunoglobulin V-like and C-like domains. Interaction of this ligand with its receptor inhibits T-cell activation and cytokine production. During infection or inflammation of normal tissue, this interaction is important for preventing autoimmunity by maintaining homeostasis of the immune response. In tumor microenvironments, this interaction provides an immune escape for tumor cells through cytotoxic T-cell inactivation. Expression of this gene in tumor cells is considered to be prognostic in many types of human malignancies, including colon cancer and renal cell carcinoma. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Sep 2015]
Alternative Names
CD274 molecule
Gene ID
UniProt ID
Field of research
Cell Biology, Immunology,
Trade name
CS1001
Groups
Approved
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Clone
CS1001
Host
Human
Species Reactivity
Human
Description
ADCC-Enhanced Anti-Human PD-L1 (CS1001) Antibody is derived from clone CS1001, which is a Human monoclonal antibody with enhanced ADCC activity. Antibody-dependent cellular cytotoxicity (ADCC) is an important function of antibody. It is a part of the humoral immune response to limit and contain infection. The antibody targets the PD-L1, and it is intended for the research of Non-small cell lung cancer.
Indication
Non-small cell lung cancer

Similar to the parental antibody CS1001, ADCC-Enhanced Anti-Human PD-L1 (CS1001) Antibody targets to the antigen PD-L1, achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK